Brain Metastases in Norway - A Prospective Cohort Study
NCT ID: NCT03346655
Last Updated: 2023-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
3000 participants
OBSERVATIONAL
2018-01-01
2024-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* What is the true incidence of BM in Norway?
* How are patients with BM treated at present?
* Do treatments differ between hospitals?
* How do treatments impact quality of life of the patients?
* Which factors (treatment, tumor and host variables) can explain disease control, survival, symptom relief, and general functions?
* How can BM staging be improved?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improved Therapy Response Assessment in Metastatic Brain Tumors
NCT03458455
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
NCT05259605
Follow-up Survey of Patients Who Were Treated for Medulloblastoma or Primitive Neuroectodermal Tumors of the Central Nervous in Norway
NCT02851355
Evaluation of the Best Treatment in Terms of Quality of Life for Patients Having a Brain Metastasis
NCT04358666
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
NCT05840575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Brain metastases verified by computer tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), or surgical biopsies
* Age ≥ 18 years
* Able to comply with study procedures
* Able to provide written informed consent after information in Norwegian
Exclusion Criteria
* Primary hematological malignancies (lymphomas, leukemias)
* Previous diagnosis and/or treatment of BM
* Unable to produce written informed consent after information in Norwegian
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Norwegian Cancer Society
OTHER
South-Eastern Norway Regional Health Authority
OTHER
Oslo University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olav Erich Yri
MD, PhD, Postdoctoral research fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olav E Yri, MD
Role: PRINCIPAL_INVESTIGATOR
Post-doc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo University Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017/1358
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.